Driving Down Early Phase Oncology Protocol Amendments
Oncology product development continues to dominate the global therapeutics market. This strength depends not only on continued use of existing products but also on the clinical and regulatory success of candidates now under development. This white paper explores key considerations and trial management issues in early phase oncology trials conducted by small- to mid-size pharmaceutical and biotechnology companies. It covers topics including the identification of key infrastructure elements that can impact clinical trial execution strategies, challenges when working with oncology patients, and provides an overview of trends in trial design and cohort management.
Submit this form for download.